SCHEMBL19934810

SCHEMBL19934810

COC(=O)c1cc(OC)cc2oc(-c3ccc(OC)cc3)c(-c3cccc(OC)c3)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.48
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2D6 P10635 2/20 0.48
▸ CYP2C9 P11712 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ ATM Q13315 1/20 0.47
▸ HPGD P15428 5/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ MAPT P10636 3/20 0.47
▸ ABCG2 Q9UNQ0 1/20 0.46
▸ ADORA3 P0DMS8 2/20 0.44
▸ SLC22A2 O15244 1/20 0.44
▸ SLC22A1 O15245 1/20 0.44
▸ CYP3A4 P08684 3/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ TP53 P04637 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ CASP1 P29466 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19934782 0.91 ALDH1A1 (0.51) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL19934809 0.87 ADORA3 (0.48) KDM4ECYP2C9CYP2C19L3MBTL1ATM
SCHEMBL28654875 0.80 KDM4E (0.50) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL30022955 0.80 KDM4E (0.50) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL30081078 0.80 ABCG2 (0.47) KDM4ECYP1A2CYP2D6L3MBTL1ATM
SCHEMBL28873061 0.80 ABCG2 (0.47) KDM4ECYP1A2CYP2D6L3MBTL1ATM
SCHEMBL19929840 0.79 L3MBTL1 (0.44) KDM4ECYP1A2CYP2C9CYP2C19L3MBTL1
SCHEMBL28873059 0.78 MEN1 (0.47) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL30081072 0.78 MEN1 (0.47) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL30081099 0.78 MAPT (0.47) KDM4ECYP1A2CYP2C9CYP2C19L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10508092-B2 Synthesis of novel analogs of diptoindonesin G, compounds formed thereby, and pharmaceutical compositions containing them WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2019-12-17 — — US disclosed
US-20180065945-A1 SYNTHESIS OF NOVEL ANALOGS OF DIPTOINDONESIN G, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY 2018-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180065945-A1 SYNTHESIS OF NOVEL ANALOGS OF DIPTOINDONESIN G, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HPGDS, DPP7, DPEP1 KDM4E 3016/4885CYP1A2 1976/4885CYP2D6 134/4885
US-10508092-B2 Synthesis of novel analogs of diptoindonesin G, compounds formed thereby, and pharmaceutical compositions containing them HPGDS, DPP7, DPEP1 KDM4E 3016/4885CYP1A2 1976/4885CYP2D6 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback